Arrowhead to Present at Upcoming Conferences

  Arrowhead to Present at Upcoming Conferences

AASLD Annual Meeting 2013 International Meeting on Molecular Biology of
Hepatitis B Viruses 2013

Business Wire

PASADENA, Calif. -- October 18, 2013

Arrowhead Research Corporation (NASDAQ:ARWR), a biopharmaceutical company
developing targeted RNAi therapeutics, today announced that it will present
data on ARC-520, its hepatitis B drug candidate, at two upcoming scientific

Scheduled conference presentations include the following:

2013 International Meeting on Molecular Biology of Hepatitis B Viruses -
Shangai, China, October 20-23, 2013

October 23, 2013 – A poster presentation titled, “Kinetics of knockdown from
RNAi therapeutic ARC-520 on hepatitis B virus RNA, DNA, S antigen and e
antigen in mice and chimpanzee,” will be presented by Christine Wooddell,
Ph.D., Senior Scientist;

AASLD – The Liver Meeting - Washington, DC, USA, November 1-5, 2013

November 3, 2013 – A poster presentation titled, “ARC-520 RNAi therapeutic
reduces HBV DNA, S and e antigen in a chimpanzee,” will be presented by Robert
E. Lanford, Ph.D., Texas Biomedical Research Institute.

About ARC-520

Approximately 350 million people worldwide are chronically infected with the
hepatitis B virus. Chronic HBV infection can lead to cirrhosis of the liver
and is responsible for 80% of primary liver cancers globally. Arrowhead’s
RNAi-based candidate ARC-520 is designed to treat chronic HBV infection by
reducing the expression and release of new viral particles and key viral
proteins. The goal is to achieve a functional cure, which is an immune
clearant state characterized by hepatitis B s-antigen negative serum with or
without sero-conversion. The siRNAs in ARC-520 intervene at the mRNA level,
upstream of where nucleotide and nucleoside analogues act. In transient and
transgenic mouse models of HBV infection, a single co-injection of Arrowhead’s
DPC delivery vehicle with cholesterol-conjugated siRNA targeting HBV sequences
resulted in multi-log knockdown of HBV RNA, proteins and viral DNA with long
duration of effect. In a chimpanzee chronically infected with HBV and high
viremia and antigenemia, ARC-520 induced rapid reductions of 90-95% in HBV
DNA, e-antigen, and s-antigen. Arrowhead has completed enrollment in a phase 1
single ascending dose study in normal volunteers, which the company expects to
follow with a phase 2a study in chronic HBV patients.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary drug
delivery technologies to develop targeted drugs based on the RNA interference
mechanism that efficiently silence disease-causing genes. Arrowhead
technologies also enable partners to create peptide-drug conjugates that
specifically home to cell types of interest while sparing off-target tissues.
Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus
and obesity and partner-based programs in oncology.

For more information please visit, or follow
us on Twitter @ArrowRes. To be added to the Company's email list to receive
news directly, please send an email to


Arrowhead Research Corporation
Vince Anzalone, CFA
The Trout Group
Lauren Glaser
Press spacebar to pause and continue. Press esc to stop.